Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-2.51Last Year’s EPS
0.45Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented strong financial health, significant progress in clinical trials, and recognition for their scientific contributions. The challenges with existing treatments in alopecia areata were acknowledged but present an opportunity for REZPEG to fill a critical need.Company Guidance
Positive Recognition for REZPEG
The Nobel Prize in Physiology or Medicine acknowledged the Phase Ib data for REZPEG in atopic dermatitis and psoriasis as part of the background documents for the award, highlighting the significance of Nektar's research.
Strong Financial Position
Nektar ended the third quarter of 2025 with $270.2 million in cash and investments, and no debt. The year-end cash guidance was increased to approximately $240 million, extending the cash runway into the second quarter of 2027.
Promising Phase IIb Results for REZPEG in Atopic Dermatitis
The RESOLVE-AD Phase IIb study showed statistical significance in all REZPEG arms versus placebo in reducing EASI scores. There is also an upcoming presentation of asthma-related data at the ACAAI meeting.
Advancement in Alopecia Areata
The Phase IIb RESOLVE-AA study in alopecia areata is on track, with results expected in December 2025. Positive results could position REZPEG as the first biologic treatment in this indication.
Pipeline Progress
Nektar's pipeline includes additional studies like the Phase II study of REZPEG in type 1 diabetes and the TNFR2 agonist program, with the potential for clinical advancement in 2026.
NKTR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NKTR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $55.12 | $55.97 | +1.54% |
Aug 07, 2025 | $21.75 | $23.06 | +6.02% |
May 08, 2025 | $9.28 | $8.83 | -4.85% |
Mar 12, 2025 | $12.30 | $12.23 | -0.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nektar Therapeutics (NKTR) report earnings?
Nektar Therapeutics (NKTR) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Nektar Therapeutics (NKTR) earnings time?
Nektar Therapeutics (NKTR) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NKTR EPS forecast?
NKTR EPS forecast for the fiscal quarter 2025 (Q4) is -2.51.